Nonsteroidal FXR Ligands: Current Status and Clinical Applications

Area of Science:

• Pharmacology
• Hepatology
• Drug Discovery

Background:

• FXR agonists show clinical promise for liver diseases like primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).
• Obeticholic acid (OCA), an FXR agonist, demonstrates efficacy in improving liver steatosis, inflammation, and fibrosis but presents liabilities including pruritus and adverse lipid profiles.
• Significant unmet medical need exists for effective NASH pharmacotherapy, driving the search for improved treatments.

Purpose of the Study:

• To review historical and ongoing efforts in identifying and developing nonsteroidal FXR agonists.
• To explore novel FXR agonists with increased potency and selectivity.
• To overcome clinical side effects associated with existing FXR agonists like OCA.

Main Methods:

• Review of literature on FXR agonist development.
• Analysis of pharmacological properties of nonsteroidal FXR agonists.
• Discussion of clinical trial outcomes and challenges.

Main Results:

• FXR agonists, including OCA, have shown efficacy in treating liver conditions.
• OCA exhibits significant liabilities, necessitating the development of alternative agents.
• Nonsteroidal FXR agonists are being investigated to enhance therapeutic profiles.

Conclusions:

• Nonsteroidal FXR agonists represent a promising therapeutic strategy for liver disorders, particularly NASH.
• Further development aims to optimize FXR agonist pharmacology for improved safety and efficacy.
• The quest for novel FXR agonists continues to address limitations of current treatments.